share_log

Johnson & Johnson Revises FY23 Adjusted EPS Guidance To $10.70-$10.80 Vs. Prior Guidance Of $10.60-$10.70 And Consensus Of $10.65; It Sees FY23 Sales Of $99.3B – $100.3B Vs. Prior Guidance Of $97.9B-$98.9B And Consensus Of $98.96B

Benzinga ·  Jul 20, 2023 06:26  · Earnings
Johnson & Johnson Revises FY23 Adjusted EPS Guidance To $10.70-$10.80 Vs. Prior Guidance Of $10.60-$10.70 And Consensus Of $10.65; It Sees FY23 Sales Of $99.3B â€" $100.3B Vs. Prior Guidance Of $97.9B-$98.9B And Consensus Of $98.96B
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment